Facebook
Twitter
LinkedIn
Forward
ART Regimens in Virologically Suppressed Patients: When Should We Make the Switch?
Once antiretroviral therapy (ART) has been initiated, patients with HIV generally remain on treatment indefinitely. For individuals on ART who have a stably suppressed plasma viral load, the patient and clinician may consider switching the regimen because of factors such as side effects or pill burden. In this setting, the goal is to maintain virologic suppression while improving the patient’s quality of life and reducing the risk of short- or long-term toxicity. Results from recent studies have shown noninferior efficacy for select 2-drug ART “switch” regimens, which offer the potential benefits of eliminating additional toxicity and interactions from a third drug as well as the possibility of reduced cost.
In this activity, Babafemi Taiwo, MBBS, and Ian Frank, MD, discuss expert recommendations for optimizing ART in virologically suppressed individuals with HIV, reasons a switch in ART regimens might be considered for a virologically suppressed patient, and general principles of regimen switching.
Target Audience
Infectious disease specialists, family and internal medicine MDs/DOs, nurse practitioners (NPs), physician assistants (PAs), and other clinicians with an interest in HIV management
Learning Objectives
- Integrate current data about toxicities (eg, weight gain, central nervous system [CNS] effects) and drug resistance when considering an HIV treatment switch
- Discuss the place of 2-drug antiretroviral therapy (ART) regimens for treatment simplification and toxicity reduction
Additional Information
Ian Frank, MD
Professor of Medicine
Director, Clinical-Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Dr. Frank is on the advisory boards of Gilead Sciences, Inc., and ViiV Healthcare.
Babafemi O. Taiwo, MBBS
Chief, Division of Infectious Diseases
Gene Stollerman Professor of Medicine
Northwestern University
Feinberg School of Medicine
Chicago, IL
Dr. Taiwo is a consultant for Gilead Sciences, Inc., Merck & Co., Inc., and ViiV Healthcare.
Accredited Provider Disclosure
The staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine has nothing to disclose with regard to commercial support.
Barry Zingman, MD, course reviewer of Albert Einstein College of Medicine has nothing to disclose with regard to commercial support.
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
Conflict of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, Albert Einstein College of Medicine and Haymarket Medical Education (HME) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME and Albert Einstein College of Medicine resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational activities.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
Accredited Providers
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 CreditTM
Accreditation Statement
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Albert Einstein College of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.25 Category 1 Credit for completing this activity.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for education activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Available Credit
- 0.25 AMA PRA Category 1 Credit™
This course is offered through MyCME. To take this course you will be redirected to MyCME's website. You must have an account with MyCME in order to complete this activity.
MOCINGBIRD continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!